A Novel Necroptosis-Related lncRNA Signature for Predicting Prognosis and Immune Response of Glioma

Figure 3

Validation of the prognostic model. (a, b) The median value and distribution of the risk scores in the training and validation cohorts. (c, d) The survival status of glioma patients with different risk scores in the training and validation cohorts. (e–h) The t-SNE and PCA plots of the training and validation cohorts. (i, j) The Kaplan-Meier curves of patients in the high-risk subgroup and low-risk subgroup in the training and validation cohorts. (k, l) The time-dependent ROC curves determined the prognostic efficacy of the risk score in the training and validation sets. (m, n) The 2-year ROC curves of risk score and clinical characteristics in the training and validation cohorts.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)

(n)